GENE ONLINE|News &
Opinion
Blog

2020-07-31| Asia-Pacific

Asia Highlights|July

by Sherry
Share To
Bill Gates-Backed SK Bioscience , Plans IPO

SK Group in South Korea is planning for another IPO of its bio affiliate, S.K. Bioscience, a vaccine developer spun-off from S.K. Chemical in July 2018. As the company said on July 26, 2020, S.K. Bioscience will start procedures to go public in the next year.

In May, The Bill & Melinda Gates Foundation-funded $3.6 million for S.K. Bioscience’s efforts to develop vaccines for Covid-19. As Bill Gates said in a letter to South Korean President Moon Jae-in, SK Bioscience might be capable of producing 200 million COVID-19 vaccine kits by June next year. Besides, the company is also one of the manufacturers who signed a contract with AstraZeneca to make its vaccines in South Korea.

S.K. Biopharmaceuticals shares were 323 times oversubscribed, buoyed by the fact that it already has approval from the US FDA for solriamfetol and cenobamate.

References

https://koreajoongangdaily.joins.com/2020/07/26/business/industry/SK-Bioscience-vaccine-IPO/20200726191300359.html


Fujifilm Thrives with U.S. Cooperation, Bags $265 Million in Grants for COVID-19 Vaccine Projects, and Novavax’s Vaccine Candidates

On July 27, 2020, the Trump administration signed a $265 million contract with the Fujifilm Texas A&M Innovation Center, the texas facility of Japan’s Fujifilm Holdings Corp, to speed up the production of a coronavirus vaccine candidate.

As Fujifilm said in a news release, the funds will speed up the expansion planned at the Texas facility in College Station. The Texas site will support Operation Warp Speed of Trump, aiming to expand the capabilities of developing and manufacturing COVID-19 vaccines and treatments in the U.S.

On July 23, 2020, Fujifilm Diosynth Biotechnologies, a drug ingredient subsidiary of Fujifilm for biologics, also announced a collaboration with Novavax to supply the active ingredients for their COVID-19 vaccine candidate, NVX-CoV2373, in the phase III trial. It was funded through Novavax’s $1.6 billion awards from Operation Warp Speed (OWS) of the federal government. Besides, in Fujifilm’s announcement, 100 million doses of NVX–CoV2373 are expected to be delivered as early as late 2020 and, therefore, benefit many patients in the U.S.

References

https://fujifilmdiosynth.com/about-us/news/novavax-and-fujifilm-diosynth-biotechnologies-initiate-large-scale-manufacturing-of-covid-19-vaccine-candidate/

By Vicky Su
Editor: Sherry Hsiao

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Bill Gates Speaks at the Illumina Genomics Forum
2022-10-01
Novavax Requires Extra Warnings One Day After Receiving Emergency Use Authorization
2022-07-18
FDA Panel Recommends Novavax To Be Fourth Authorized COVID-19 Vaccine in America
2022-06-08
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!